Targeting Genetic Drivers of Rare Genitourinary Cancers

Video

This video reviews new studies examining the genetic drivers of three rare genitourinary cancers: von Hippel-Lindau disease, advanced papillary renal cell carcinoma, and penile cancer.

In this video, Guru Sonpavde, MD, of the University of Alabama at Birmingham Comprehensive Cancer Center, reviews three new studies involving rare genitourinary cancers: a phase II study of pazopanib in von Hippel-Lindau disease (abstract 4516), a comprehensive genomic profiling of advanced papillary renal cell carcinoma (abstract 4517), and a multiregion sequencing of penile cancer that revealed actionable mutations (abstract 4519).

Sonpavde was the discussant during a poster discussion session on the identification and targeting of genetic drivers of rare genitourinary cancers, which featured these three studies, at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, held last month in Chicago.

Recent Videos
Collaboration among different medical and research institutions may help improve quality of care for patients with cancer exposed to climate disasters.
A radiation oncologist discussed the theranostics treatment landscape and career opportunities in the field at the 2025 ACRO Summit.
Findings from the OVARIO study show that patients with HRR–deficient and BRCA-mutated disease benefitted the most from niraparib/bevacizumab maintenance.
A study assessed whether physicians would keep patients who received NSCLC surgery in the hospital longer as an improvisational strategy after wildfires.
Related Content